Alvespimycin : Alvespimycin is identified as a novel therapeutic agent for diabetic kidney disease by chemical screening targeting extracellular vesicles
Ozanimod: A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists